Tango Therapeutics terminated a prior at-the-market offering program that had sold approximately $64.4 million of shares and filed a new prospectus supplement to raise up to $400 million in aggregate proceeds. The company operates in the biotechnology industry, focusing on developing cancer treatments.

Tango Therapeutics reported second quarter 2026 financial results on August 11, 2026. The company held $1.0 billion in cash as of June 30, 2026. Net loss for the three months ended June 30 was $55.3 million, or $0.37 per share, compared to a net loss of $38.9 million in the prior year period. Research and development expenses increased to $37.2 million from $32.8 million, while general and administrative expenses rose to $22.6 million from $11.3 million due to personnel-related costs. The company announced key leadership appointments, including Fatma Ocak as Chief Commercialization Officer effective August 17, 2026, and Robert Azelby as Chairman of the Board. Clinical updates highlighted a 92% objective response rate for vopimetostat combined with daraxonrasib in pancreatic cancer, supporting plans to advance into Phase 3 development.

Tango Therapeutics, Inc. amended its prior Form 8-K to disclose the executed separation agreement with Executive Chair Barbara Weber, M.D., whose employment ended on August 3, 2026. The agreement provides severance pay through December 31, 2026, COBRA premium reimbursement until that date, a pro-rata portion of her 2026 annual incentive compensation payable by March 15, 2027, and full acceleration of outstanding option and restricted stock unit awards subject to Compensation Committee approval. Additionally, the post-termination exercise period for vested options is extended to August 3, 2027 or their original expiration date. This executive departure constitutes a material change in leadership for the clinical-stage biotechnology company focused on discovering precision cancer medicines via synthetic lethality.

Tango Therapeutics, Inc. announced that Dr. Barbara Weber’s employment as Executive Chair ended on August 3, 2026, resulting in her resignation from all officer and board positions. The separation agreement provides severance pay through December 31, 2026, COBRA premium reimbursement until the same date, acceleration of equity vesting for twelve months post-termination, an extended option exercise period, and a pro-rata annual incentive payment by March 15, 2027. The resignation was not due to disagreements regarding operations or policies. Tango Therapeutics, Inc. operates in the biotechnology industry, focusing on developing targeted therapies for cancer.

Tango Therapeutics, Inc. expanded its Board of Directors to seven members on June 19, 2026, with the appointment of Robert Azelby. Mr. Azelby will serve as a Class II director and join the Compensation and Nominating and Corporate Governance Committees effective June 23, 2026. His compensation includes an annual retainer of $45,000 for board service, $7,500 for compensation committee service, and $5,000 for governance committee service. Additionally, he received an equity award comprising 35,910 stock options at an exercise price of $27.97 and 5,740 restricted stock units. Tango Therapeutics, Inc. is a biotechnology company focused on developing precision medicines.

Tango Therapeutics, Inc. entered into an underwriting agreement on June 9, 2026, to conduct an underwritten offering of 18,166,667 shares of common stock at $30.00 per share and 1,833,395 pre-funded warrants at $29.999 per warrant. The offering includes a 30-day option for underwriters to purchase up to 3,000,009 additional shares. The company expects net proceeds of approximately $566.5 million, which it intends to use for research and development, pivotal trial expenses, and general corporate purposes. Management believes these funds will extend its operating runway into 2030. Tango Therapeutics is a biotechnology company focused on developing precision medicines.